CE/CME

Pediatric T2DM: A Growing Threat to US Health

Although accreditation for this CE/CME activity has expired, and the posttest is no longer available, you can still read the full article.

Expires March 31, 2016

The increasing prevalence of type 2 diabetes mellitus (T2DM) in children and adolescents is a serious health threat that urgently requires effective lifestyle intervention in at-risk patients, vigilant disease management for those diagnosed, and further research to support treatment decisions in the pediatric population.


 

References


CE/CME No: CR-1503

PROGRAM OVERVIEW
Earn credit by reading this article and successfully completing the posttest and evaluation. Successful completion is defined as a cumulative score of at least 70% correct.

EDUCATIONAL OBJECTIVES
• Differentiate between pediatric type 1 diabetes mellitus (T1DM) and type 2 DM (T2DM) and definitively establish the diagnosis.
• Understand the link between pediatric obesity and T2DM and help the patient and family incorporate healthy eating and physical activity habits into their lifestyle.
• Describe the scope of treatment options for pediatric T2DM and the importance of monitoring glycemic control to ensure that treatment goals are met.
• Explain the long-term health risks associated with pediatric T2DM and how to screen for complications in order to initiate early treatment.
• Establish a health care team with the primary care clinician, T2DM specialists, and the patient’s family to create an individualized plan of care for your pediatric patient with T2DM.

FACULTY
Ashlyn Smith is an endocrinology PA at Endocrinology Associates in Scottsdale, Arizona. The author has no significant financial relationships to disclose.

ACCREDITATION STATEMENT

This program has been reviewed and is approved for a maximum of 1.0 hour of American Academy of Physician Assistants (AAPA) Category 1 CME credit by the Physician Assistant Review Panel. [NPs: Both ANCC and the AANP Certification Program recognize AAPA as an approved provider of Category 1 credit.] Approval is valid for one year from the issue date of March 2015.

Article begins on next page >>

Pages

Recommended Reading

Breast Cancer Patients Show Poor Adherence to Cardiovascular, Diabetes Medications
Clinician Reviews
No Increased Pancreatitis Risk Found With Incretin Therapy
Clinician Reviews
Early Prediabetes Treatment Reduces HbA1C During Pregnancy
Clinician Reviews
Lenvima Gets the FDA’s Nod for Differentiated Thyroid Cancer
Clinician Reviews
Diabetes and Steroid Use
Clinician Reviews
Seven Years of Hot Flashes Common During, After Menopause
Clinician Reviews
Skip This Step When Checking Lipid Levels
Clinician Reviews
Megestrol Acetate for CKD and Dialysis Patients
Clinician Reviews
Can Vitamin D Supplements Help With Hypertension?
Clinician Reviews
Oral Bisphosphonates Linked with Lower Risk of Endometrial Cancer
Clinician Reviews

Related Articles